MX2020006671A - Proteinas de fusion. - Google Patents

Proteinas de fusion.

Info

Publication number
MX2020006671A
MX2020006671A MX2020006671A MX2020006671A MX2020006671A MX 2020006671 A MX2020006671 A MX 2020006671A MX 2020006671 A MX2020006671 A MX 2020006671A MX 2020006671 A MX2020006671 A MX 2020006671A MX 2020006671 A MX2020006671 A MX 2020006671A
Authority
MX
Mexico
Prior art keywords
domain
fusion target
target
cells
binding
Prior art date
Application number
MX2020006671A
Other languages
English (en)
Inventor
Francis Jay Mussai
Santo Carmela De
Steven Lee
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2020006671A publication Critical patent/MX2020006671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
    • C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)

Abstract

Se proporcionan proteínas de fusión de unión al blanco que comprenden una fracción de unión al blanco, una región de señalización intracelular y un dominio que promueve la síntesis de arginina o un precursor de arginina. El dominio puede ser un dominio enzimático tal como un dominio de la enzima argininosuccinato sintasa (ASS-1), o un dominio de la enzima ornitina transcarbamilasa (OTC). También se proporcionan células que comprenden dicha proteína de fusión de unión al blanco (por ejemplo, células que expresan la proteína de fusión de unión al blanco), y ácidos nucleicos que codifican dichas proteínas de fusión de unión al blanco. La invención también proporciona proteínas de fusión de unión al blanco que comprenden una fracción de unión al blanco, una región de señalización intracelular y un dominio que promueve la síntesis de triptófano o un precursor de triptófano. Son divulgadas composiciones farmacéuticas, usos médicos y método de tratamiento, todos utilizando las proteínas de fusión de unión al blanco o ácidos nucleicos. Las proteínas, células, ácidos nucleicos y composiciones farmacéuticas se pueden usar en la prevención y/o tratamiento del cáncer, como neuroblastoma o leucemia mieloide aguda.
MX2020006671A 2017-12-22 2018-12-24 Proteinas de fusion. MX2020006671A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1721833.0A GB201721833D0 (en) 2017-12-22 2017-12-22 Fusion proteins
PCT/GB2018/053771 WO2019122936A1 (en) 2017-12-22 2018-12-24 Fusion proteins

Publications (1)

Publication Number Publication Date
MX2020006671A true MX2020006671A (es) 2020-10-28

Family

ID=61131454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006671A MX2020006671A (es) 2017-12-22 2018-12-24 Proteinas de fusion.

Country Status (14)

Country Link
US (1) US20200308557A1 (es)
EP (1) EP3728299A1 (es)
JP (1) JP2021507716A (es)
KR (1) KR20200110347A (es)
CN (1) CN111770933A (es)
AU (1) AU2018387430A1 (es)
BR (1) BR112020012717A2 (es)
CA (1) CA3085925A1 (es)
GB (1) GB201721833D0 (es)
IL (1) IL275560A (es)
MX (1) MX2020006671A (es)
SG (1) SG11202005761SA (es)
WO (1) WO2019122936A1 (es)
ZA (1) ZA202003845B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113736812A (zh) * 2021-09-06 2021-12-03 武汉翼康基因科技有限公司 一种pcMINI载体及其构建方法与应用
WO2023131285A1 (zh) * 2022-01-07 2023-07-13 原启生物科技(上海)有限责任公司 靶向cldn18.2和msln的嵌合抗原受体及其用途
CN115779097B (zh) * 2022-11-09 2024-01-30 四川大学 基于工程化线粒体的肿瘤抗原递送系统及应用
CN116003638B (zh) * 2023-01-20 2023-09-05 北京基因启明生物科技有限公司 一种有效杀伤胆管型肝癌的CAR-iNKT细胞技术

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420150B1 (en) * 2000-11-27 2002-07-16 Pe Corporation (Ny) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2003103597A2 (en) * 2002-06-05 2003-12-18 Metabolex, Inc Methods of diagnosing & treating diabetes and insulin resistance
CN102215836B (zh) * 2008-09-19 2015-07-08 雀巢产品技术援助有限公司 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持
CN106220739A (zh) * 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
BR112013018311A2 (pt) * 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
JP2016512199A (ja) * 2013-03-05 2016-04-25 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 腫瘍溶解性ウイルス
US10287331B2 (en) * 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
US8912147B2 (en) * 2013-04-15 2014-12-16 BioBlast Pharma Ltd. Mitochondrial proteins constructs and uses thereof
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
ES2791953T3 (es) * 2014-06-06 2020-11-06 Us Health Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
EP3169703B2 (en) * 2014-07-16 2023-12-13 Hinrich Abken Chimeric antigen receptor and its use
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6784687B2 (ja) * 2015-02-24 2020-11-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法

Also Published As

Publication number Publication date
BR112020012717A2 (pt) 2020-11-24
WO2019122936A1 (en) 2019-06-27
GB201721833D0 (en) 2018-02-07
SG11202005761SA (en) 2020-07-29
CN111770933A (zh) 2020-10-13
KR20200110347A (ko) 2020-09-23
IL275560A (en) 2020-08-31
CA3085925A1 (en) 2019-06-27
ZA202003845B (en) 2022-12-21
EP3728299A1 (en) 2020-10-28
AU2018387430A1 (en) 2020-07-09
JP2021507716A (ja) 2021-02-25
US20200308557A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2020006671A (es) Proteinas de fusion.
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2018160754A3 (en) Inducible monovalent antigen binding protein
CA3011049A1 (en) Compositions for linking dna-binding domains and cleavage domains
WO2018083087A3 (en) Binding proteins
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2021013783A (es) Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus.
MX371033B (es) Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
WO2018081592A3 (en) Compositions and methods for the production of compounds
MX346950B (es) Reovirus que tienen secuencias modificadas.
WO2015063747A3 (en) Peptide inhibitors of tead/yap-taz interaction
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.